3m Innovative Properties Company

Minnesota Mining and Manufacturing Company

Adamis Pharmaceuticals Corporation

James S Stefely

Daniel C Duan

Stephen W Stein

Jimmie Rae Baran, Jr

David W Schultz

Chester L Leach

Steven S Kantner

Craig Allen Perman

Brian J Gabrio

Nancy J Rustad

Michael W Mueting

Herbert C Chiou

Luke E Schallinger

Thomas Edward Wood

Robert A Scherrer

John T Capecchi

Madeline P Shinbach

John E Gozum

Peter M Seiler

Manfred E Riechert

Kathleen A Dennison

Richard C Kao

Monserrat R La Londe

Kelvin J Witcher

Hye-Ok Choi

Joanne M Bartkus

Jimmie R Baran

Disclosed herein are powder mixing apparatuses and methods that utilize the deagglomerizing and mixing effects of an air flow that impacts a flowing powder. The resulting powder can have smaller particle sizes and/or exhibit a more homogenous mixture than the premixed powder.

Powder mixing apparatus and method of use

Powder compositions exhibiting improved flow properties. The compositions generally contain a bulk solid material in the form of a powder and surface-modified nanoparticles. Methods of improving the flow of powder compositions and devices and articles made using such compositions are also disclosed.

Compositions exhibiting improved flowability

The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising a functionalized polyethyleneglycol, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient comprising a functionalized polyethyleneglycol.

Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula &#x2014;[X&#x2014;R&#x2014;C(O)]&#x2014; wherein each Ris an independently selected organic group that links the &#x2014;X&#x2014; group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Biocompatible compounds for sustained release pharmaceutical drug delivery systems

Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula &#x2014;[O&#x2014;R&#x2014;C(O)]&#x2014; wherein: 'R' is a linear, branched, or cyclic organic group, 'n' is at least three, (b) Acylating the biocompatible polymer to provide an acylated biocompatible polymer and a mixed anhydride; (c) Reacting the mixed anhydride with a nucleophile to provide an acylated biocompatible polymer with a terminal carboxylic acid derivative capable of being chemically converted to an acid in the absence of water, (d) Converting the terminal carboxylic acid derivative to an acylated biocompatible polymer with a terminal carboxylic acid; and (e) Combining the acylated biocompatible polymer with a drug to provide the medicinal composition.

Medicinal compositions and method for the preparation thereof

In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase.

Methods of treating mammals with stabilized particle dispersions containing excipient surface-modified nanoparticles

The invention relates to stabilized dispersions containing nanoparticles of use for the administration of medicaments. The dispersions comprise excipient nanoparticles, a dispersed phase comprising medicament and a continuous phase comprising propellant.

Stabilized aerosol dispersions

Stabilized dispersions comprising excipient surface-modified organic nanoparticles and medicament particles

The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.

Medicinal aerosol compositions with an amide and/or ester containing excipient compound

The invention relates to stabilized gas-in-liquid dispersions or foams containing a liquid continuous phase, a dispersed gas phase, and surface-modified fullerenes, dendrimers, organic polymeric microspheres, or combinations thereof.

Stabilized foams including surface-modified organic molecules

Stabilized particle dispersions containing nanoparticles

The invention is related to emulsions containing surface-modified organic molecules, organic polymeric microspheres, or combinations thereof.

Emulsions including surface-modified organic molecules

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula &mdash;&lsqb;X&mdash;R &mdash;C(O)&rsqb;&mdash; wherein each R is an independently selected organic group that links the &mdash;X&mdash; group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Medicinal aerosol solution formulation with biocompatible polymer

Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula --[X--R.sup.1 --C(O)]-- wherein each R.sup.1 is an independently selected organic group that links the --X-- group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Growing community of inventors

Woodbury, MN, United States of America

James S Stefely